...To the original response that Gottlieb misses the point: I think you're missing his point.I'm not missing his point at all, in fact, I'm acknowleging the NEJM study may or may not be valid (In actuality I'm not a fan of metastudies.) What I am doing is adding an additional point that gives what I believe is one of the explanations why NEJM and others have become increasingly hostile towards pharma. My post yesterday "Drug Makers Finance Nurses as On-Site, Chart-Reviewing Drug Reps" is yet another example of how pharma shoots itself in the foot with regard to social trust.